Skip to main content

Advertisement

Table 4 Association between (EORTC QLQ-C30, EORTC QLQ-BR23) functioning and symptom scales with GQoL of patients with breast cancer at TASH, Addis Ababa, Ethiopia

From: Health-related quality of life and its predictors among patients with breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia

  Variable GQOL COR (95% CI) AOR (95% CI)
Affected Not affected
EORTC QLQ C-30 Functional scales
 Physical functioning Affected 187 (68.0) 46 (35.7) 3.83 (2.47–5.96)  
Not affected 88 (32.0) 83 (64.3) 1.00  
 Role Functioning Affected 139 (50.5) 18 (14.0) 6.30 (3.63–10.94)  
Not affected 136 (49.5) 111 (86.0) 1.00  
 Emotional Functioning Affected 134 (48.7) 30 (23.3) 3.14 (1.96–5.03)  
Not affected 141 (51.3) 99 (76.7) 1.00  
 Cognitive Functioning Affected 121 (44.0) 23 (17.8) 3.62 (2.18–6.03) 2.38 (1.32–4.31)*
Not affected 154 (56.0) 106 (82.2) 1.00 1.00
 Social Functioning Affected 104 (37.8) 27 (20.9) 2.29 (1.41–3.75)  
Not affected 171 (62.2) 102 (79.1) 1.00  
Symptom scales
 Fatigue Affected 204 (74.2) 45 (34.9) 5.36 (3.41–8.43)  
Not affected 71 (25.8) 84 (65.1) 1.00  
 Nausea and Vomiting Affected 87 (31.6) 14 (10.9) 3.80 (2.07–6.99)  
Not affected 188 (68.4) 115 (89.1) 1.00  
 Pain Affected 195 (70.9) 26 (20.2) 9.66 (5.84–15.96) 7.99 (4.62–13.83)*
Not affected 80 (29.1) 103 (79.8) 1.00 1.00
 Dyspnoea Affected 113 (41.1) 18 (14.0) 4.30 (2.47–7.48)  
Not affected 162 (58.9) 111 (86.0) 1.00  
 Insomnia Affected 152 (55.3) 37 (28.7) 3.07 (1.96–4.82)  
Not affected 123 (44.7) 92 (71.3) 1.00  
 Appetite loss Affected 166 (60.4) 38 (29.5) 3.65 (2.33–5.72)  
Not affected 109 (39.6) 91 (70.5) 1.00  
 Constipation Affected 122 (44.4) 35 (27.1) 2.14 (1.36–3.38)  
Not affected 153 (55.6) 94 (72.9) 1.00  
 Diarrhea Affected 27 (9.8) 7 (5.4) 1.89 (0.80–4.48)  
Not affected 248 (90.2) 122 (94.6) 1.00  
 Financial Difficulties Affected 187 (68.0) 54 (41.9) 2.95 (1.92–4.55) 2.60 (1.56–4.35)*
Not affected 88 (32.0) 75 (58.1) 1.00 1.00
EORTC QLQ BR-23 Functional scales
 Sexual functioning Affected 70 (25.5) 50 (38.8) 0.54 (0.35–0.84)  
Not affected 205 (74.5) 79 (61.2) 1.00  
 Future Perspective Affected 181 (65.8) 61 (47.3) 2.15 (1.40–3.29) 2.08 (1.24–3.49)*
Not affected 94 (34.2) 68 (52.7) 1.00 1.00
Symptom scales
 Systemic therapy side effects Affected 184 (66.9) 44 (34.1) 3.91 (2.51–6.08)  
Not affected 91 (33.1) 85 (65.9) 1.00  
 Breast Symptoms Affected 109 (39.6) 24 (18.6) 2.87 (1.73–4.76)  
Not affected 166 (60.4) 105 (81.4) 1.00  
 Arm symptoms Affected 119 (43.3) 28 (21.7) 2.75 (1.70–4.46)  
Not affected 156 (56.7) 101 (78.3) 1.00  
  1. AOR Adjusted Odd’s Ratio, COR crudes Odd’s Ratio